FDA will re-evaluate safety of diabetes drug Avandia, sources say

The FDA plans to ask a panel of experts to conduct a safety review of GlaxoSmithKline's Avandia in response to complaints from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, about the risk of heart attack associated with the diabetes drug, sources said. FDA Commissioner Margaret Hamburg will gather "FDA scientists and outside experts to gain a full understanding and awareness of all of the data and issues involved," an agency spokeswoman said.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ